Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge
Nucleic Acid Insights · 2024
DOI: 10.18609/nai.2024.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Insights, 2024. Verfasst von Ansgar Santel und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The COVID-19 pandemic catapulted mRNA into the spotlight—but what wider impacts did this success have on the field? David McCall, Senior Editor, Nucleic Acid Insights, speaks to Ansgar Santel, CEO and Jörg Kaufmann, CSO, of Pantherna Therapeutics about the latest developments in the mRNA–LNP space, tackling myths and safety concerns surrounding cationic lipids, and Pantherna’s approach to solving the issue of moving beyond hepatocyte targeting.
Zitieren
APA
Santel, A., & Kaufmann, J. (2024). Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge. Nucleic Acid Insights. https://doi.org/10.18609/nai.2024.022
Vancouver
Santel A, Kaufmann J. Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge. Nucleic Acid Insights. 2024. doi:10.18609/nai.2024.022
BibTeX
@article{Santel2024,
author = {Santel, Ansgar and Kaufmann, Jörg},
title = {Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge},
journal = {Nucleic Acid Insights},
year = {2024},
doi = {10.18609/nai.2024.022}
}
EUVIMED